Home›Trial›NCT04580420
🔬NCT04580420Phase 2RECRUITING

Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

Study Summary

The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

Conditions
Primary Hyperoxaluria Type 1End Stage Renal Disease
Interventions / Drugs
DCR-PHXC
View on ClinicalTrials.gov ↗
Sponsor
NVO
Novo Nordisk
Diabetes/Obesity
F9/100
Study Details
Enrollment28 participants
Primary Completion—
Lead SponsorDicerna Pharmaceuticals, Inc., a Novo Nordisk company
Data Retrieved2026-04-11 02:55:47.366893+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.